Physician profile
Reza B Omid
NPI 1386869717
$400,428.35
in general payments reported to CMS, 2019-2025
7 companies · $43K in 2025
The $43K reported for 2025 was more than what 94% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $57K · 2021: $44K · 2022: $56K · 2023: $66K · 2024: $44K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $129K · Honoraria: $14K · Consulting Fee: $10K · Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $128,592.58 |
| Honoraria | $14,350.00 |
| Consulting Fee | $10,150.00 |
| Food and Beverage | $265.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $212,524.42 | 2019-2025 | Titan, Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Integra Lifesciences Corporation | $148,277.94 | 2019-2021 | |
| Encore Medical, Lp | $25,074.89 | 2021-2025 | Djo Surgical |
| Medacta USA, INC. | $13,736.39 | 2019-2025 | Mecta |
| Ascension Orthopedics, INC. | $750.00 | 2020 | |
| Depuy Synthes Sales INC. | $40.50 | 2025 | Na, Va-Lcp |
| Ethicon US, LLC | $24.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Omid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.